156 related articles for article (PubMed ID: 35897894)
1. Harnessing Protein-Ligand Interaction Fingerprints to Predict New Scaffolds of RIPK1 Inhibitors.
Aniceto N; Marques V; Amaral JD; Serra PA; Moreira R; Rodrigues CMP; Guedes RC
Molecules; 2022 Jul; 27(15):. PubMed ID: 35897894
[TBL] [Abstract][Full Text] [Related]
2. Profiling of small-molecule necroptosis inhibitors based on the subpockets of kinase-ligand interactions.
Xu L; Zhuang C
Med Res Rev; 2023 Nov; 43(6):1974-2024. PubMed ID: 37119044
[TBL] [Abstract][Full Text] [Related]
3. Sibiriline, a new small chemical inhibitor of receptor-interacting protein kinase 1, prevents immune-dependent hepatitis.
Le Cann F; Delehouzé C; Leverrier-Penna S; Filliol A; Comte A; Delalande O; Desban N; Baratte B; Gallais I; Piquet-Pellorce C; Faurez F; Bonnet M; Mettey Y; Goekjian P; Samson M; Vandenabeele P; Bach S; Dimanche-Boitrel MT
FEBS J; 2017 Sep; 284(18):3050-3068. PubMed ID: 28715128
[TBL] [Abstract][Full Text] [Related]
4. Using Machine Learning and Molecular Docking to Leverage Urease Inhibition Data for Virtual Screening.
Aniceto N; Albuquerque TS; Bonifácio VDB; Guedes RC; Martinho N
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175889
[TBL] [Abstract][Full Text] [Related]
5. A computational study to target necroptosis via RIPK1 inhibition.
Bepari AK; Takebayashi H; Namme JN; Rahman GMS; Reza HM
J Biomol Struct Dyn; 2023; 41(14):6502-6517. PubMed ID: 35938618
[TBL] [Abstract][Full Text] [Related]
6. Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis.
Hou J; Ju J; Zhang Z; Zhao C; Li Z; Zheng J; Sheng T; Zhang H; Hu L; Yu X; Zhang W; Li Y; Wu M; Ma H; Zhang X; He S
Cell Death Dis; 2019 Jun; 10(7):493. PubMed ID: 31235688
[TBL] [Abstract][Full Text] [Related]
7. Discovery, optimization and evaluation of isothiazolo[5,4-b]pyridine derivatives as RIPK1 inhibitors with potent in vivo anti-SIRS activity.
Hao Y; Yang C; Shu C; Li Z; Xia K; Wu S; Ma H; Tian S; Ji Y; Li J; He S; Zhang X
Bioorg Chem; 2022 Dec; 129():106051. PubMed ID: 36115309
[TBL] [Abstract][Full Text] [Related]
8. Proposing novel TNFα direct inhibitor Scaffolds using fragment-docking based e-pharmacophore modeling and binary QSAR-based virtual screening protocols pipeline.
Zaka M; Abbasi BH; Durdagi S
J Mol Graph Model; 2018 Oct; 85():111-121. PubMed ID: 30149308
[TBL] [Abstract][Full Text] [Related]
9. RIPK1 inhibitor Cpd-71 attenuates renal dysfunction in cisplatin-treated mice via attenuating necroptosis, inflammation and oxidative stress.
Wang JN; Liu MM; Wang F; Wei B; Yang Q; Cai YT; Chen X; Liu XQ; Jiang L; Li C; Hu XW; Yu JT; Ma TT; Jin J; Wu YG; Li J; Meng XM
Clin Sci (Lond); 2019 Jul; 133(14):1609-1627. PubMed ID: 31315969
[TBL] [Abstract][Full Text] [Related]
10. Discovery and optimization of 3-(indolin-5-yloxy)pyridin-2-amine derivatives as potent necroptosis inhibitors.
Lan Y; Ji Y; Peng X; Duan W; Geng M; Ai J; Zhang H
Arch Pharm (Weinheim); 2024 Jul; ():e2400302. PubMed ID: 38955770
[TBL] [Abstract][Full Text] [Related]
11. Antioxidant and food additive BHA prevents TNF cytotoxicity by acting as a direct RIPK1 inhibitor.
Delanghe T; Huyghe J; Lee S; Priem D; Van Coillie S; Gilbert B; Choi SM; Vandenabeele P; Degterev A; Cuny GD; Dondelinger Y; Bertrand MJM
Cell Death Dis; 2021 Jul; 12(7):699. PubMed ID: 34262020
[TBL] [Abstract][Full Text] [Related]
12. Generative deep learning enables the discovery of a potent and selective RIPK1 inhibitor.
Li Y; Zhang L; Wang Y; Zou J; Yang R; Luo X; Wu C; Yang W; Tian C; Xu H; Wang F; Yang X; Li L; Yang S
Nat Commun; 2022 Nov; 13(1):6891. PubMed ID: 36371441
[TBL] [Abstract][Full Text] [Related]
13. Applications of Quantitative Structure-Activity Relationships (QSAR) based Virtual Screening in Drug Design: A Review.
Achary PGR
Mini Rev Med Chem; 2020; 20(14):1375-1388. PubMed ID: 32348219
[TBL] [Abstract][Full Text] [Related]
14. Discovery of potential RIPK1 inhibitors by machine learning and molecular dynamics simulations.
Liu JX; Na RS; Yang LJ; Huang XR; Zhao X
Phys Chem Chem Phys; 2023 Nov; 25(45):31418-31430. PubMed ID: 37962373
[TBL] [Abstract][Full Text] [Related]
15. A novel small molecule Hsp90 inhibitor, C-316-1, attenuates acute kidney injury by suppressing RIPK1-mediated inflammation and necroptosis.
Liu XQ; Liu MM; Jiang L; Gao L; Zhang Y; Huang YB; Wang X; Zhu W; Zeng HX; Meng XM; Wu YG
Int Immunopharmacol; 2022 Jul; 108():108849. PubMed ID: 35588657
[TBL] [Abstract][Full Text] [Related]
16. Ensemble pharmacophore meets ensemble docking: a novel screening strategy for the identification of RIPK1 inhibitors.
Fayaz SM; Rajanikant GK
J Comput Aided Mol Des; 2014 Jul; 28(7):779-94. PubMed ID: 24980648
[TBL] [Abstract][Full Text] [Related]
17. Bayesian machine learning to discover Bruton's tyrosine kinase inhibitors.
Wang J; Ran T; Chen Y; Lu T
Chem Biol Drug Des; 2020 Oct; 96(4):1114-1122. PubMed ID: 31855311
[TBL] [Abstract][Full Text] [Related]
18. Selection of Promising Novel Fragment Sized
Shulga DA; Kudryavtsev KV
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946760
[TBL] [Abstract][Full Text] [Related]
19. 3D-QSAR, Virtual Screening, Docking and Design of Dual PI3K/mTOR Inhibitors with Enhanced Antiproliferative Activity.
Oluić J; Nikolic K; Vucicevic J; Gagic Z; Filipic S; Agbaba D
Comb Chem High Throughput Screen; 2017 Aug; 20(4):292-303. PubMed ID: 28460621
[TBL] [Abstract][Full Text] [Related]
20. Identification of the Raf kinase inhibitor TAK-632 and its analogues as potent inhibitors of necroptosis by targeting RIPK1 and RIPK3.
Chen X; Zhuang C; Ren Y; Zhang H; Qin X; Hu L; Fu J; Miao Z; Chai Y; Liu ZG; Zhang H; Cai Z; Wang HY
Br J Pharmacol; 2019 Jun; 176(12):2095-2108. PubMed ID: 30825190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
